Young Kwang Chae, Professor and Co-Director of Developmental Therapeutics, Lurie Cancer Center at Northwestern University, shared on X:
“An Insightful Editorial in Transplant Oncology!
An editorial published in JAMA Surgery by Dr. Michael S. Mulligan and colleagues evaluates our landmark prospective registry data from the DREAM (Double Lung Transplant Registry Aimed for Lung-Limited Malignancies) study, examining bilateral lung transplantation for patients with medically refractory, lung-limited Stage IV Non-Small Cell Lung Cancer (NSCLC).
Key Takeaways and Detailed Insights
- Exceptional Early Survival: In carefully selected patients with lung-limited Stage IV NSCLC facing terminal respiratory failure, double lung transplant achieved a 100% 1-year overall survival rate, compared to 40.8% in contemporaneous eligible control patients managed with standard care.
- A Novel Conceptual Solution: For metastatic disease strictly confined to the lungs driven by intrapulmonary dissemination, complete bilateral lung replacement enables total organ-level disease removal in a single intervention when all conventional systemic therapies are exhausted.
- Non-Inferior Outcomes vs. Non-Cancer Transplants: The 1-year post-transplant survival in the cancer cohort was non-inferior to contemporaneous patients undergoing lung transplantation for non-malignant end-stage lung disease (88.1%) – challenging long-held guidelines that categorically list active malignancy as an absolute contraindication.
- Ethical and Oncologic Considerations: While 1-year survival is a major milestone, the authors stress that 3- to 5-year follow-up and multi-center validation are critical to assess long-term recurrence risks under post-transplant immunosuppression and to refine ethical organ allocation policies.”
Title: Lung Transplant for Stage IV NSCLC – A Promising Intervention in a Scarce-Resource Environment
Authors: Michael S. Mulligan, Jay D. Pal, Erika D. Lease.
Read the full article.
This also can be interesting:
